TVTX Travere Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
20:30
Aug 27
Aug 27
Travere is the global commercialization and development partner for Everest's lead asset, and is credited with deep nephrology expertise and prior FDA approvals, strengthening its pipeline beyond its current assets.
HIGH
11:28
Aug 17
Aug 17
Piper Sandler, Wells Fargo, Jefferies, Barclays, D.A.
Piper Sandler, Wells Fargo, Jefferies, Barclays, D.A. Davidson, Stifel, and TD Cowen raised price targets across a broad list of stocks including RIGL, SAIL, S, SNOW, SUI, SKT, TGT, HD, TVTX, VEEV, and ZS.
20:04
Aug 13
Aug 13
Author complains their short book is underperforming while longs dominate.
Author complains their short book is underperforming while longs dominate, listing prior short candidates as context rather than fresh trade calls.
10:47
Aug 12
Aug 12
Incoming competition to erode TVTX market share
Short TVTX as incoming competitive pressure is expected to structurally erode the company's market share, providing a clear deterioration mechanism beyond simple valuation criticism.
MED
About TVTX Analyst Coverage
Buzzberg tracks TVTX (Travere Therapeutics, Inc.) across 3 sources. 0 bullish vs 1 bearish calls from 3 analysts. Sentiment: mixed to bearish. 4 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Ian Wu, DeItaone, seedy19tron.